rPIV5- and AVLP-vectored vaccine development with public tumor-specific neoantigens

使用公共肿瘤特异性新抗原开发 rPIV5 和 AVLP 载体疫苗

基本信息

  • 批准号:
    10831315
  • 负责人:
  • 金额:
    $ 14.67万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-05-11 至 2026-04-30
  • 项目状态:
    未结题

项目摘要

Abstract This application is being submitted in response to the Notice of Special Interest (NOSI) identified as NOT-CA- 23-045. The proposed supplement project aims to validate the immunogenicity of a total 10 public tumor- specific neoantigen (pTSNA) candidates identified by our parent R01CA252713 project, entitled “Canine MHC- I genotyping and tumor specific neoantigen determination”. These are defined as mutant peptides that are: 1) derived from hotspot mutations in canine and human cancers; and 2) predicted to bind MHC class I (MHC-I) alleles dominant in canine/human populations and/or subpopulations (breeds or ethnic groups). We will collaborate with Drs. Biao He and Dong An, two leading vaccine developers to perform two studies. 1) We will clone the pTSNA candidates in tandem into vaccine vectors parainfluenza virus 5 (PIV5) and PIV5- based self-amplifying virus-like particle (AVLP). PIV5 and AVLP, developed by Drs He and An, are ideal vaccine vectors especially for cancer vaccine development, as they elicit more robust cellular immune responses, compared to other strategies. 2) We will infecting peripheral blood mononuclear cells (PBMCs) isolated from dogs harboring the required MHC-I alleles with rPIV5-pTSNA and rAVLP-pTSNA viruses, identify pTSNAs that are presented by the MHC-I alleles via mass-spectrometry, and identify immunogenic pTSNAs via interferon-g assays. This proposed supplement study will significantly enhance Aim 2c of the parent R01, by accelerating immunogenic pTSNA discovery. Furthermore, the study will yield critical reagents (rPIV5-pTSNA amd rAVLP- pTSNA vaccines) and knowledge for future cancer vaccine development that impacts a large population of both dogs and humans. The study is especially significant, considering that PIV5-based vaccines are shown to be safe and immunogenic for dogs, and PIV5-based vaccines are often administrated intranasally.
摘要 本申请是为了响应被标识为NOT-CA的特别利益通知(NOSI)而提交的- 23-045.该补充项目旨在验证10种公共肿瘤的免疫原性, 特异性新抗原(pTSNA)候选物,其由我们的父R 01 CA 252713项目,题为“犬MHC- I基因分型和肿瘤特异性新抗原测定”。这些被定义为突变肽,其为:1) 来源于犬和人癌症中的热点突变;和2)预测结合MHC I类(MHC-I) 等位基因在犬/人类群体和/或亚群(品种或种族群体)中占优势。 我们将与两位领先的疫苗开发者何彪和董安博士合作进行两项研究。第一章 我们将pTSNA候选物串联克隆到疫苗载体副流感病毒5型(PIV 5)和PIV 5 - 1中。 自扩增病毒样颗粒(AVLP)。由何博士和安博士开发的PIV 5和AVLP是理想的 疫苗载体,特别是用于癌症疫苗开发,因为它们引起更强大的细胞免疫 与其他策略相比。2)我们将感染外周血单个核细胞(PBMC) 从携带所需MHC-I等位基因的rPIV 5-pTSNA和rAVLP-pTSNA病毒的犬中分离,鉴定 通过质谱分析由MHC-I等位基因呈递的pTSNA,并鉴定免疫原性pTSNA 通过干扰素-g测定。 这项拟议的补充研究将通过加速 免疫原性pTSNA发现。此外,该研究将产生关键试剂(rPIV 5-pTSNA和rAVLP-pTSNA)。 pTSNA疫苗)和未来癌症疫苗开发的知识, 狗和人类都是。这项研究尤其重要,因为基于PIV 5的疫苗显示出 对于狗是安全的和免疫原性的,并且基于PIV 5的疫苗通常鼻内施用。

项目成果

期刊论文数量(7)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
A Kmer-based paired-end read de novo assembler and genotyper for canine MHC class I genotyping.
基于kmer的配对末端读取从头汇编器和犬MHC I类基因分型的Genotyper。
  • DOI:
    10.1016/j.isci.2023.105996
  • 发表时间:
    2023-02-17
  • 期刊:
  • 影响因子:
    5.8
  • 作者:
    Feng, Yuan;Hess, Paul R.;Tompkins, Stephen M.;Hildebrand, William H.;Zhao, Shaying
  • 通讯作者:
    Zhao, Shaying
Canine major histocompatibility complex class I (MHC-I) diversity landscape.
犬主要组织相容性复合体 I 类 (MHC-I) 多样性景观。
  • DOI:
    10.1101/2024.02.14.580220
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Feng,Yuan;Ho,Kun-Lin;Zhang,Mengyuan;Sundaresha,NikithaBrahmasamudra;Cavanagh,HannahLorelle;Zhao,Shaying
  • 通讯作者:
    Zhao,Shaying
Canine tumor mutational burden is correlated with TP53 mutation across tumor types and breeds.
  • DOI:
    10.1038/s41467-021-24836-9
  • 发表时间:
    2021-08-03
  • 期刊:
  • 影响因子:
    16.6
  • 作者:
    Alsaihati BA;Ho KL;Watson J;Feng Y;Wang T;Dobbin KK;Zhao S
  • 通讯作者:
    Zhao S
Shared hotspot mutations in oncogenes position dogs as an unparalleled comparative model for precision therapeutics.
  • DOI:
    10.1038/s41598-023-37505-2
  • 发表时间:
    2023-07-06
  • 期刊:
  • 影响因子:
    4.6
  • 作者:
    Rodrigues, Lucas;Watson, Joshua;Feng, Yuan;Lewis, Benjamin;Harvey, Garrett;Post, Gerald;Megquier, Kate;White, Michelle E.;Lambert, Lindsay;Miller, Aubrey;Lopes, Christina;Zhao, Shaying
  • 通讯作者:
    Zhao, Shaying
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

William Hildebrand其他文献

William Hildebrand的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('William Hildebrand', 18)}}的其他基金

Canine MHC-I genotyping and tumor specific neoantigen determination
犬 MHC-I 基因分型和肿瘤特异性新抗原测定
  • 批准号:
    10404109
  • 财政年份:
    2021
  • 资助金额:
    $ 14.67万
  • 项目类别:
Canine MHC-I genotyping and tumor specific neoantigen determination
犬 MHC-I 基因分型和肿瘤特异性新抗原测定
  • 批准号:
    10630913
  • 财政年份:
    2021
  • 资助金额:
    $ 14.67万
  • 项目类别:
Canine MHC-I genotyping and tumor specific neoantigen determination
犬 MHC-I 基因分型和肿瘤特异性新抗原测定
  • 批准号:
    10220542
  • 财政年份:
    2021
  • 资助金额:
    $ 14.67万
  • 项目类别:
Human natural killer cell recognition of cytomegalovirus
人类自然杀伤细胞对巨细胞病毒的识别
  • 批准号:
    8617610
  • 财政年份:
    2014
  • 资助金额:
    $ 14.67万
  • 项目类别:
Direct Discovery of HLA-associated Influenza Epitopes
HLA 相关流感表位的直接发现
  • 批准号:
    8481492
  • 财政年份:
    2012
  • 资助金额:
    $ 14.67万
  • 项目类别:
Direct Discovery of HLA-associated Influenza Epitopes
HLA 相关流感表位的直接发现
  • 批准号:
    8434472
  • 财政年份:
    2012
  • 资助金额:
    $ 14.67万
  • 项目类别:
Discovery and Targeting of HIV-1 Associated Antigens
HIV-1 相关抗原的发现和靶向
  • 批准号:
    8106378
  • 财政年份:
    2010
  • 资助金额:
    $ 14.67万
  • 项目类别:
Discovery and Targeting of HIV-1 Associated Antigens
HIV-1 相关抗原的发现和靶向
  • 批准号:
    7984351
  • 财政年份:
    2010
  • 资助金额:
    $ 14.67万
  • 项目类别:
Discovery and Targeting of HIV-1 Associated Antigens
HIV-1 相关抗原的发现和靶向
  • 批准号:
    8493984
  • 财政年份:
    2010
  • 资助金额:
    $ 14.67万
  • 项目类别:
Discovery and Targeting of HIV-1 Associated Antigens
HIV-1 相关抗原的发现和靶向
  • 批准号:
    8288353
  • 财政年份:
    2010
  • 资助金额:
    $ 14.67万
  • 项目类别:

相似海外基金

Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
  • 批准号:
    502556
  • 财政年份:
    2024
  • 资助金额:
    $ 14.67万
  • 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
  • 批准号:
    10659303
  • 财政年份:
    2023
  • 资助金额:
    $ 14.67万
  • 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
  • 批准号:
    10674405
  • 财政年份:
    2023
  • 资助金额:
    $ 14.67万
  • 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
  • 批准号:
    10758772
  • 财政年份:
    2023
  • 资助金额:
    $ 14.67万
  • 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
  • 批准号:
    10676499
  • 财政年份:
    2023
  • 资助金额:
    $ 14.67万
  • 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
  • 批准号:
    2748611
  • 财政年份:
    2022
  • 资助金额:
    $ 14.67万
  • 项目类别:
    Studentship
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
  • 批准号:
    10532032
  • 财政年份:
    2022
  • 资助金额:
    $ 14.67万
  • 项目类别:
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
  • 批准号:
    22K05630
  • 财政年份:
    2022
  • 资助金额:
    $ 14.67万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
  • 批准号:
    10525070
  • 财政年份:
    2022
  • 资助金额:
    $ 14.67万
  • 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
  • 批准号:
    10689017
  • 财政年份:
    2022
  • 资助金额:
    $ 14.67万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了